Related Experiment Video
Updated: Mar 30, 2026
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
The pathogenesis of soluble PrP fragments containing Aβ binding sites
1Department of Otorhinolaryngology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, PR China.
Abstract:
Prion protein (PrP) has proven to bind amyloid beta (Aβ) oligomers with high affinity, changing our understanding of both prion diseases (PD) and Alzheimer's disease (AD) at the molecular and phenotypic levels, although the latter currently lacks sufficient attentions. Transgenic mice expressing anchorless PrP developed unusual diseases reminiscent of AD with tremendous amyloid plaque formation. In this review, we described two interesting observations at the phenotypic level. First, common pathogenic mutations of the PRNP gene in Gerstmann-Sträussler-Scheinker (GSS) syndrome were clustered at PrP95-105. Meanwhile, all nonsense PRNP mutations that generated soluble PrP 95-105 exhibited phenotypes with abundant amyloid formations. We speculate that PrP-Aβ oligomers binding might be the underlying mechanism of the predominant amyloid phenotypes. Second, soluble PrP-Aβ oligomer complexes might exist in the extracellular space at the beginning of both PD and AD and subserve an initial neuroprotective function. Thus, the diseases would only present after long-term accumulation. This might be the central common pathogenic event of both PD and AD.
Insights
Prion protein (PrP) binding to amyloid beta (Aβ) oligomers may explain amyloid plaque formation in prion diseases (PD) and Alzheimer's disease (AD). This interaction might initially protect against neurodegeneration before disease onset.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Prion protein (PrP) binds amyloid beta (Aβ) oligomers, impacting prion diseases (PD) and Alzheimer's disease (AD).
- Transgenic mice with anchorless PrP exhibit Alzheimer's-like pathology with amyloid plaques.
- The molecular and phenotypic overlap between PD and AD warrants further investigation.
Purpose of the Study:
- To review the phenotypic observations linking PrP-Aβ interactions to amyloid formation in neurodegenerative diseases.
- To explore the potential common pathogenic mechanisms between PD and AD.
- To investigate the role of PrP-Aβ oligomer binding in disease initiation and progression.
Main Methods:
- Review of existing literature on prion protein (PrP) and amyloid beta (Aβ) interactions.
- Analysis of phenotypic data from transgenic mouse models.
- Examination of PRNP gene mutations associated with Gerstmann-Sträussler-Scheinker (GSS) syndrome.
Main Results:
- Pathogenic PRNP mutations in GSS are clustered at PrP95-105, correlating with amyloid formation.
- Nonsense PRNP mutations producing soluble PrP 95-105 also lead to abundant amyloid phenotypes.
- PrP-Aβ oligomer binding is hypothesized as the mechanism driving amyloid phenotypes in these conditions.
Conclusions:
- PrP-Aβ oligomer binding may be the central common pathogenic event in both PD and AD.
- Soluble PrP-Aβ oligomer complexes might offer initial neuroprotection before long-term accumulation leads to disease.
- Understanding this interaction is crucial for deciphering the molecular basis of these neurodegenerative diseases.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils